Exelixis Inc

Find Ratings Reports
EXEL : NASDAQ : Health Care
$8.71 | %
Today's Range: 0.00 - 0.00
Avg. Daily Volume: 6,221,100
07/25/16 - 4:00 PM ET

Financial Analysis


EXELIXIS INC's gross profit margin for the first quarter of its fiscal year 2016 has significantly decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. EXELIXIS INC is extremely liquid. Currently, the Quick Ratio is 3.29 which clearly shows the ability to cover any short-term cash needs. The company managed to increase its liquidity from the same period a year ago, despite already having strong liquidity to begin with. This would indicate improved cash flow.

During the same period, stockholders' equity ("net worth") has decreased by 6.26% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY16 Q1 FY15
Net Sales ($mil)15.439.39
EBITDA ($mil)-48.81-22.89
EBIT ($mil)-49.04-23.19
Net Income ($mil)-61.35-35.17


Balance Sheet Q1 FY16 Q1 FY15
Cash & Equiv. ($mil)322.12113.35
Total Assets ($mil)492.53282.93
Total Debt ($mil)388.66368.43
Equity ($mil)-155.95-146.76


Profitability Q1 FY16 Q1 FY15
Gross Profit Margin-316.41-243.86
EBITDA Margin-316.4-243.86
Operating Margin-317.89-247.03
Sales Turnover0.090.1
Return on Assets-39.77-80.97
Return on Equity0.00.0
Debt Q1 FY16 Q1 FY15
Current Ratio3.362.13
Debt/Capital1.671.66
Interest Expense12.4112.4
Interest Coverage-3.95-1.87


Share Data Q1 FY16 Q1 FY15
Shares outstanding (mil)228.68196.02
Div / share0.00.0
EPS-0.27-0.18
Book value / share-0.68-0.75
Institutional Own % n/a n/a
Avg Daily Volume6241557.04370356.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
EXEL NM Peers 40.39   EXEL 30.01 Peers 21.72

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

EXEL's P/E is negative making this valuation measure meaningless.

 

Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

EXEL is trading at a significant premium to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
EXEL NM Peers 122.62   EXEL NA Peers 1.15

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

EXEL's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
EXEL NM Peers 11.16   EXEL 23.73 Peers -19.12

Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

EXEL's P/B is negative making this valuation measure meaningless.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

EXEL is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
EXEL 45.46 Peers 425.82   EXEL 46.01 Peers 40.81

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

EXEL is trading at a significant discount to its industry on this measurement.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

EXEL has a sales growth rate that exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades